ConvaTec Group Plc stock (GB00BD3VFW73): analyst consensus and recent share move on LSE

ConvaTec Group Plc shares on the London Stock Exchange have been trading around the low-200 pence range, while a group of analysts continues to see upside over the next 12 months based on their latest price targets and ratings.

ConvaTec Group Plc shares on the London Stock Exchange have recently been quoted around the low-200 pence area, with one snapshot showing the stock at 202.85 GBX on 05/29/2026, underscoring how the United Kingdom-listed medtech name remains in focus among investors according to data highlighted by MarketBeat as of 05/29/2026.

As a home-market reference point, the stock trades on the LSE under the ticker CTEC and forms part of the London healthcare universe; in one recent London South East market overview, ConvaTec was cited at 197.80p intraday, down about 2.2% on that session, illustrating how the share price can move within a fairly tight band in day-to-day trading according to London South East coverage as of 05/29/2026.

The stock traded at 202.85 GBX on 05/29/2026 on the London Stock Exchange, according to MarketBeat as of 05/29/2026, providing a recent UK price marker for ConvaTec shares.

From a continental European point of view, ConvaTec is also accessible to German investors via platforms such as Tradegate, where the stock is quoted in EUR and thus connects the United Kingdom-based medtech group with demand from the broader DACH region, although liquidity remains centered on the home listing in London.

On the fundamental side, ConvaTec continues to be profiled in sector overviews of the wound care and broader medtech markets, with one acute wound care market report listing ConvaTec Group alongside names such as Mölnlycke Health Care, Smith & Nephew, Acelity and Ethicon as key players in products for acute wound management, reflecting the company’s ongoing role in this specialist healthcare niche according to OpenPR as of 05/31/2026.

In another thematic piece on UK medtech names, ConvaTec Group is described as operating across continence and ostomy care, wound care and infusion care, emphasizing how its product portfolio is diversified across several categories that serve chronic and acute patient needs, according to Kalkine Media as of 02/03/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ConvaTec
• Sector/industry: Medical technology and wound care
• Headquarters/country: Reading, United Kingdom
• Core markets: Europe, North America and other international healthcare markets
• Key revenue drivers: Ostomy and continence care, advanced wound care and infusion care products
• Home exchange/listing venue: London Stock Exchange (CTEC)
• Trading currency: GBP

ConvaTec Group Plc: core business model

ConvaTec Group focuses on specialized medical technology, generating revenue primarily from ostomy and continence solutions, advanced wound dressings and infusion care products used across hospitals, clinics and home-care settings.

What banks and research houses say about ConvaTec Group Plc

According to a consolidated overview from MarketBeat, as of 05/29/2026 the consensus rating for ConvaTec Group shares stands at "moderate buy" across research analysts, with an average 12-month price target of 308.78 GBX based on nine contributing analyst forecasts, implying substantial upside versus the 202.85 GBX reference price cited for that date, as detailed by MarketBeat as of 05/29/2026.

Within that same consensus framework, the highest analyst price target is reported at 375 GBX and the lowest at 230 GBX, which illustrates a range of views on the stock’s potential value over the coming year but still clusters above the last traded level, underlining that professional coverage remains constructive overall on the UK-listed name according to MarketBeat as of 05/29/2026.

Conclusion

For ConvaTec Group, the latest trading levels on the London Stock Exchange around the low-200 pence mark provide the backdrop against which investors interpret the company’s role in wound care, ostomy and infusion products within the wider United Kingdom healthcare sector.

The current analyst consensus, summarized as a "moderate buy" stance with an average 12-month target price well above the recent share price, highlights how research houses view the stock’s risk-reward profile, even as day-to-day moves remain relatively contained in London trading.

How the market reconciles that supportive analyst view with upcoming company-specific news, broader medtech trends and overall equity sentiment will likely be key for the next phase of the ConvaTec Group share price story on the LSE and related European trading venues.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.